Navin Fluorine International Limited (NAVINFLUOR) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 31, 2026 3 min read

Navin Fluorine International is a leading Indian specialty chemical manufacturer, currently navigating a complex transition as it scales high-value CDMO and Advanced Materials segments while managing global commodity price volatility. Investors are looking for clarity on the commissioning status of major capex projects and the impact of rising input costs on the company's full-year margin guidance.

Quick Details

Results date	August 05, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 938 Cr
Previous quarter PAT	Rs. 213 Cr
Previous quarter EBITDA margin	34.2%
Market cap	Rs. 38606.86 Cr
CMP	Rs. 7524.75

Navin Fluorine International Limited Q1 Results Date and Time

The board meeting is scheduled for August 05, 2026, to consider the audited financial results.

The earnings call is scheduled for August 05, 2026, at 06:30 PM IST with Chairman Vishad Mafatlal, MD Nitin Kulkarni, and CFO Anish Ganatra.

What to expect from Navin Fluorine International Limited's Q1 FY27 results

Navin Fluorine enters Q1 FY27 with a strong base, having achieved Rs. 3,314 Cr in revenue for FY26, and is now testing its ability to maintain double-digit growth against a challenging prior-year quarter that saw Rs. 725 Cr in revenue. While the company benefits from a roughly 7.5% currency tailwind due to the USD/INR movement compared to Q1 FY26, management must navigate a sharp rise in sulfur prices, which have climbed from approximately $550/t to $1,000–1,100/t. Despite these input cost pressures, the company's CDMO segment, supported by a portfolio of 55–60 active molecules, remains a key driver for visibility, with management reaffirming a full-year EBITDA margin target of 30% (±1–2%). The upcoming call will likely focus on whether the Chemours project and the Advanced Materials liquid cooling unit achieved their targeted June 2026 commissioning milestones.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against the company's stated FY27 operational and financial targets.

Revenue Growth — double-digit YoY — Q1 FY27 print
EBITDA Margin — 30% (±1-2%) full-year target — Q1 trajectory
Chemours Project — late June/early July 2026 commissioning — status update
Advanced Materials Project — Q1 FY27 commissioning — status update
HFC Capacity Expansion (R32) — Q3 FY27 commissioning — progress update

Strategic Execution and Capex: Updates on recent partnerships and infrastructure scaling.

DRDO Collaboration — first update on Sodium Borohydride project terms and timeline
Renewable Energy SPV Acquisitions — status of 5 MW and 3.30 MW captive power projects for Dahej and Surat units
MPP De-bottlenecking — on track for Q3 FY27 commissioning

Risks and Headwinds to Monitor: Management-flagged factors impacting operational performance.

US Tariff Impact — assessment of temporary vs permanent status for the 20% of sales exposed to US markets
Input Cost Inflation — sulfur and fluorspar price trends and pass-through effectiveness
Agrochemical Demand — volume recovery pace amid a slow market reset

Frequently Asked Questions

How does the company manage raw material price volatility?

Management utilizes pass-through mechanisms in CDMO contracts to mitigate cost inflation. For other segments, they monitor input costs closely and work to reflect higher prices in their product pricing decisions.

What is the status of the CDMO segment's revenue visibility?

The company maintains strong revenue visibility for the next three years driven by cGMP-4 commercial supplies. It currently manages a portfolio of approximately 55-60 active molecules.

Is the company on track with its FY27 EBITDA margin guidance?

Management reaffirmed the 30% EBITDA margin guidance for FY27 during the Q4 FY26 call. They emphasize this is a full-year target with an allowance of ±1-2% variance.

How did the company's revenue grow in the previous fiscal year?

Net revenue grew 41% YoY to Rs. 3,314 Cr in FY26, supported by strong performance across high-performance products, specialty chemicals, and CDMO segments. This growth was accompanied by an EBITDA margin expansion of 992 bps to 32.6%.